Upstate Active Clinical Trials
Study Title:2215-CL-0201: A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Upstate Institutional Review Board (IRB) Number:890706
Patient Age Group:Adults
Principal Investigator:Teresa C Gentile, MD, PhD
Where will the study take place?Upstate Cancer Center - All Procedures
Who can I contact for more information?
Name: Alexandra Koulouris, BA